An Article 29 referral procedure was initiated due to concerns raised by the CZ and LV on the potential serious risk to public health regarding insufficient proof of bioequivalence since the Applicant did not use the originator´s products (Aulin Gel) as reference treatments but used monocomponent-containing generics in the originally submitted bioequivalence study.